1-cyclohexyl-2-isocyanatobenzene | 1022158-39-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-cyclohexyl-2-isocyanatobenzene
• CAS: 1022158-39-9
• 化学式: C₁₃H₁₅NO
• 分子量: 201.268
• InChiKey: WIVMAYNBFWLJGI-UHFFFAOYSA-N

物化性质

• 沸点：
  285.0±19.0 °C(predicted)
• 密度：
  1.07±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-cyclohexyl-2-isocyanatobenzene 、 2,3-diaminomaleonitrile 以 乙腈 为溶剂， 反应 72.0h， 生成
  参考文献：
  名称：

  WO2008/51494

  摘要：

  公开号：
• 作为产物：
  描述：

  2-cyclohexylbenzoyl azide 以 甲苯 为溶剂， 反应 1.0h， 以100%的产率得到1-cyclohexyl-2-isocyanatobenzene
  参考文献：
  名称：

  WO2008/51494

  摘要：

  公开号：

文献信息

• Compounds having beta adrenergic receptor agonist and muscarinic receptor antagonist activity
  申请人：Mammen Mathai

  公开号：US20060035933A1

  公开（公告）日：2006-02-16

  This invention provides compounds of formula I: wherein R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8a , R 8b , W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β 2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

  这项发明提供了式I的化合物：其中R1、R2、R4、R5、R6、R7、R8a、R8b、W、a、b、c和m如规范中所定义，或其药学上可接受的盐、溶剂或立体异构体。本发明的化合物具有β2肾上腺素受体激动剂和肌碱受体拮抗剂活性。因此，这些化合物预计可用作治疗肺部疾病，如慢性阻塞性肺病和哮喘的治疗剂。
• COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
  申请人：Mammen Mathai

  公开号：US20090239904A1

  公开（公告）日：2009-09-24

  This invention provides compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8a , R 8b , W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β 2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

  此发明提供公式I的化合物：其中R1，R2，R3，R4，R5，R6，R7，R8a，R8b，W，a，b，c和m如规范中所定义，或其药学上可接受的盐或溶剂或立体异构体。本发明的化合物具有β2肾上腺素受体激动剂和肌动蛋白受体拮抗剂活性。因此，这些化合物预计可用作治疗肺部疾病，如慢性阻塞性肺疾病和哮喘的治疗剂。
• Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
  申请人：Theravance, Inc.

  公开号：US07569586B2

  公开（公告）日：2009-08-04

  This invention provides compounds of formula I: wherein R1, R2, R3, R4,R5, R6, R7, R8a, R8b, W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

  本发明提供了I式化合物：其中R1、R2、R3、R4、R5、R6、R7、R8a、R8b、W、a、b、c和m如规范中所定义，或其药学上可接受的盐或溶剂或立体异构体。本发明的化合物具有β2肾上腺素受体激动剂和毒蕈碱受体拮抗剂活性。因此，这些化合物预计可用作治疗肺部疾病，如慢性阻塞性肺疾病和哮喘的治疗剂。
• Method of using compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
  申请人：Theravance, Inc.

  公开号：US08143277B2

  公开（公告）日：2012-03-27

  This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

  本发明提供了I式化合物：其中R1、R2、R3、R4、R5、R6、R7、R8a、R8b、W、a、b、c和m如规范中所定义，或其药学上可接受的盐或溶剂或立体异构体。本发明的化合物具有β2肾上腺素受体激动剂和毒蕈碱受体拮抗剂活性。因此，这些化合物预计可用作治疗肺部疾病，如慢性阻塞性肺疾病和哮喘的治疗剂。
• Waterborne polyurethane dispersions
  申请人：SANNCOR INDUSTRIES, INC.

  公开号：EP0373671A2

  公开（公告）日：1990-06-20

  Polyurethane dispersions are described that are resistant to water and alcohol, exhibit a long pot life, and produce a hard, high gloss finish without the need for a curing step, and which are suitable as coatings and/or adhesives for wood, concrete, natural and synthetic fibers, plastic films etc. Such a composition comprises a polymerized blend of a first component consisting essentially of a mixture solely of aro­matic diisocyanates or of one or more aromatic diisocyanates with one or more aliphatic diisocyanates; a second component consisting essentially of one or more polyhydroxyl compounds; and a polyhydroxyl compound containing a carboxyl moiety.

  聚氨酯分散体具有耐水和耐酒精的特性，具有较长的罐装寿命，无需固化步骤即可获得坚硬的高光泽表面，适用于木材、混凝土、天然纤维和合成纤维、塑料薄膜等的涂层和/或粘合剂。这种组合物由以下成分的聚合混合物组成：第一种成分，主要由芳香族二异氰酸酯或一种或多种芳香族二异氰酸酯与一种或多种脂肪族二异氰酸酯的混合物组成；第二种成分，主要由一种或多种多羟基化合物组成；以及一种含有羧基的多羟基化合物。